Sanjay Kaul, MD

All posts by Sanjay Kaul, MD

RSS

December 8th, 2014

New Anticoagulant Spotlights Major Role for the Intrinsic Pathway

and

Sanjay Kaul and Ethan Weiss discuss an entirely new approach to anticoagulation.


August 26th, 2013

Missing Data And The ATLAS ACS 2-TIMI 51 Trial

and

What is the impact of the larger than usual amount of missing data in the ATLAS ACS 2-TIMI 51? A member of the FDA’s Cardiovascular and Renal Drugs Advisory panel answers questions about this issue.


April 2nd, 2013

Perspective On The Controversy About The TACT Trial

The NIH TACT trial of chelation therapy has been the subject of intense criticism. In my opinion, the arguments that the TACT results are dubious or not valid are overstated. While the debate surrounding TACT is clearly warranted and welcome, I hope it generates more light than heat.


August 10th, 2011

Rethinking Trilipix — And the Process for Approving Lipid-Modifying Drugs

Editor’s Note: In an article published in the New England Journal of Medicine, three members of the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (Allison Goldfine, Sanjay Kaul, and William Hiatt) offer their perspective on the May 19 committee meeting to review the controversial ACCORD-Lipid Study. Here, one of those authors, Sanjay Kaul, provides his […]


October 6th, 2010

Study Finds No Evidence for Clopidogrel-Omeprazole Interaction

and

A large clinical trial has found no evidence that omeprazole interferes with the cardiovascular efficacy of clopidogrel. COGENT (Clopidogrel and the Optimization of Gastrointestinal Events Trial) randomized 3873 patients eligible for dual antiplatelet therapy to receive aspirin, clopidogrel, and either omeprazole or placebo. The COGENT investigators had planned to enroll 5000 patients, but the trial […]


August 6th, 2010

Three Questions about Ticagrelor: Part 4 — Bob Harrington

PLATO is one of the most impressive trials in recent years, demonstrating substantial benefits for ticagrelor over clopidogrel in a wide population of ACS patients. However, patients enrolled in the US showed no benefit from ticagrelor, and experts have been unable to agree on a cause. Possible factors could include much higher doses of aspirin used in the […]


August 5th, 2010

Three Questions about Ticagrelor: Part 3 — Jonathan Halperin

PLATO is one of the most impressive trials in recent years, demonstrating substantial benefits for ticagrelor over clopidogrel in a wide population of ACS patients. However, patients enrolled in the US showed no benefit from ticagrelor, and experts have been unable to agree on a cause. Possible factors could include much higher doses of aspirin used in the […]


August 4th, 2010

Three Questions about Ticagrelor: Part 2 — Mori Krantz

PLATO is one of the most impressive trials in recent years, demonstrating substantial benefits for ticagrelor over clopidogrel in a wide population of ACS patients. However, patients enrolled in the US were found to have no benefit from ticagrelor, and experts have been unable to agree on a cause. Possible factors could include much higher doses […]


August 4th, 2010

Research Suggests Possible New Early Strategies for HCM

CardioExchange welcomes Carolyn Ho to discuss her study in the New England Journal of Medicine, which looked at myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy (HCM). Her team found that levels of serum C-terminal propeptide of type I procollagen (PICP) were higher in mutation carriers without LVH and in patients with HCM than […]


August 3rd, 2010

Three Questions about Ticagrelor: Part 1 — Sanjay Kaul

PLATO is one of the most impressive trials in recent years, demonstrating substantial benefits for ticagrelor over clopidogrel in a wide population of ACS patients. However, patients enrolled in the US showed no benefit from ticagrelor, and experts have been unable to agree on a cause. Possible factors could include much higher doses of aspirin used […]